TCGA-55-8514-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.370
- KRAS_SIGNALING_DN+0.290
- CHOLESTEROL_HOMEOSTASIS+0.190
- INTERFERON_GAMMA_RESPONSE+0.170
- IL6_JAK_STAT3_SIGNALING+0.150
- TNFA_SIGNALING_VIA_NFKB+0.130
- COAGULATION+0.100
- INFLAMMATORY_RESPONSE+0.090
- PANCREAS_BETA_CELLS+0.090
- MYOGENESIS+0.080
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.600
- MITOTIC_SPINDLE-0.450
- MTORC1_SIGNALING-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- OXIDATIVE_PHOSPHORYLATION-0.380
- PROTEIN_SECRETION-0.380
- PI3K_AKT_MTOR_SIGNALING-0.370
- TGF_BETA_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.862 |
| 2 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.851 |
| 3 | MDT-AP-2296 | Med | Medulloblastoma | 0.845 |
| 4 | BS_94MT16N2 | pilocytic astrocytoma | — | 0.843 |
| 5 | TCGA-CF-A47S-01A-11R-A23W-07 | — | — | 0.843 |
| 6 | TCGA-MN-A4N5-01A-11R-A24X-07 | — | cohortA1 | 0.840 |
| 7 | TCGA-49-AARN-01A-21R-A41B-07 | — | cohortA1 | 0.833 |
| 8 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.831 |
| 9 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.830 |
| 10 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |